If you or a loved one have been struggling with depression that hasn’t responded to traditional treatments, there’s new hope on the horizon. Georgia Behavioral Health is proud to offer Spravato (esketamine), a groundbreaking medication that’s transforming the landscape of mental health care.
Spravato is a nasal spray medication containing esketamine, a form of ketamine. It’s the first new medication approved for treatment-resistant depression (TRD) in decades. While traditional antidepressants work by targeting serotonin or norepinephrine, Spravato works differently, acting on the brain’s glutamate system. This novel mechanism of action has been shown to rapidly reduce depressive symptoms in many individuals who haven’t found relief with other treatments.
TRD is a type of major depressive disorder (MDD) that hasn’t responded to at least two different antidepressant medications at adequate doses and durations. It’s a challenging condition that can leave individuals feeling hopeless and discouraged.
Spravato is not a first-line treatment for depression, but it can be a life-changing option for those who haven’t responded to other treatments. If you’ve been diagnosed with TRD, it’s worth discussing with your provider to see if Spravato may be appropriate for you.
At Georgia Behavioral Health, we provide a safe, supportive environment for Spravato treatment. Our experienced team will closely monitor your progress and work with you to personalize your treatment plan. We’re committed to helping you find lasting relief from depression and regain control of your life.
If you’re struggling with treatment-resistant depression, don’t lose hope. Contact Georgia Behavioral Health today to learn more about Spravato and how it could make a difference in your life.